English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/151417
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids

AuthorsCaretti, Anna; Vasso, Michele; Bonezzi, Fabiola Tecla; Gallina, Andrea; Trinchera, Marco; Rossi, Alice; Adami, Raffella; Casas, Josefina ; Falleni, Monica; Tosi, Delfina; Bragonzi, Alessandra; Ghidoni, Riccardo; Gelfi, Cecilia; Signorelli, Paola
KeywordsCeramide
Cystic fibrosis
Inflammation
Mass Spectrometry
Myriocin
Issue Date24-Apr-2017
PublisherSpringer
CitationNaunyn Schmiedeberg's Archives of Pharmacology 390: 1–16 (2017)
AbstractOur aim was to use quantitative and qualitative analyses to gain further insight into the role of ceramide in cystic fibrosis (CF). Sphingolipid ceramide is a known inflammatory mediator, and its accumulation in inflamed lung has been reported in different types of emphysema, chronic obstructive pulmonary disease and CF. CF is caused by a mutation of the chloride channel and associated with hyperinflammation of the respiratory airways and high susceptibility to ongoing infections. We have previously demonstrated that de novo ceramide synthesis is enhanced in lung inflammation and sustains Pseudomonas aeruginosa pulmonary infection in a CF murine model. We used liquid chromatography and matrix-assisted laser desorption/ionization (MALDI) imaging coupled with mass spectrometry, confocal laser scan microscopy and histology analyses to reveal otherwise undecipherable information. We demonstrated that (i) upregulated ceramide synthesis in the alveoli is strictly related to alveolar infection and inflammation, (ii) alveolar ceramide (C16) can be specifically targeted by nanocarrier delivery of the ceramide synthesis inhibitor myriocin (Myr) and (iii) Myr is able to downmodulate pro-inflammatory lyso-PC, favouring an increase in anti-inflammatory PCs. We concluded that Myr modulates alveolar lipids milieu, reducing hyperinflammation and favouring anti-microbial effective response in CF mouse model. © 2017 Springer-Verlag Berlin Heidelberg
Publisher version (URL)10.1007/s00210-017-1373-4
URIhttp://hdl.handle.net/10261/151417
DOI10.1007/s00210-017-1373-4
Appears in Collections:(IQAC) Artículos
Files in This Item:
File Description SizeFormat 
17 Naunyn Sch Arch Pharmacol maldi preprint-1.pdf2,28 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.